Flex Pharma Inc (NASDAQ:FLKS) – Research analysts at Jefferies Group issued their FY2022 earnings per share estimates for shares of Flex Pharma in a research report issued to clients and investors on Tuesday. Jefferies Group analyst M. Andrews expects that the biotechnology company will post earnings of ($0.08) per share for the year.
A number of other equities research analysts also recently weighed in on FLKS. Zacks Investment Research raised Flex Pharma from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a report on Friday, December 1st. Ladenburg Thalmann Financial Services began coverage on Flex Pharma in a report on Thursday, January 25th. They issued a “buy” rating and a $12.00 target price on the stock. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $10.00 target price on shares of Flex Pharma in a report on Wednesday, January 17th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Flex Pharma in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $9.79.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its stake in shares of Flex Pharma by 67.1% in the 4th quarter. Renaissance Technologies LLC now owns 89,900 shares of the biotechnology company’s stock valued at $314,000 after acquiring an additional 36,100 shares during the last quarter. Sphera Funds Management LTD. lifted its stake in shares of Flex Pharma by 70.7% in the 4th quarter. Sphera Funds Management LTD. now owns 241,211 shares of the biotechnology company’s stock valued at $4,339,000 after acquiring an additional 99,911 shares during the last quarter. Granite Point Capital Management L.P. lifted its stake in shares of Flex Pharma by 80.8% in the 4th quarter. Granite Point Capital Management L.P. now owns 71,520 shares of the biotechnology company’s stock valued at $250,000 after acquiring an additional 31,961 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of Flex Pharma by 10.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 720,524 shares of the biotechnology company’s stock valued at $2,457,000 after acquiring an additional 65,699 shares during the last quarter. Institutional investors own 27.26% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://sportsperspectives.com/2018/02/14/jefferies-group-comments-on-flex-pharma-incs-fy2022-earnings-flks.html.
About Flex Pharma
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.